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A B S T R A C T
The diagnosis and treatment of von Willebrand disease (VWD) are challenging, in part because patients exhibit a
wide range of bleeding patterns and manifestations (e.g. epistaxis, gingival bleeding, heavy menstrual bleeding,
gastrointestinal bleeds, postoperative bleeding, hemarthroses) and in part because many tests are required to
make an accurate diagnosis. Factor replacement therapies for VWD are the mainstay of treatment for patients
who do not respond to desmopressin. They have gradually evolved from crude preparations of plasma proteins to
plasma-derived concentrates containing both von Willebrand factor (VWF) and factor VIII (FVIII). However,
varying amounts and quality of VWF and varying content of FVIII have contributed to the lack of a standardized
approach to replacement therapy. More recently, the treatment of VWD has undergone a slow yet significant
change from plasma-derived VWF/FVIII concentrates with VWF:ristocetin cofactor (RCo)/FVIII ratios ≤1, to
those with VWF:RCo/FVIII ratios> 10, to a recombinant VWF. This article reviews the evolution of factor
replacement therapy for patients with VWD that has occurred over the last several decades. The availability of a
greater variety of factor replacement therapies poses a challenge in terms of a standard algorithm of care but
may help overcome the limitations of earlier treatments and allow treatment personalization according to in-
dividual patient needs.
1. Introduction
Since its initial description in 1926, von Willebrand disease (VWD)
has posed a diagnostic and therapeutic challenge [1]. VWD is the most
common inherited bleeding disorder in the world, with an estimated
prevalence of symptomatic disease of ~1 in 1000 individuals [2,3].
VWD results from a deficiency or a defect in von Willebrand factor
(VWF), a multimeric plasma glycoprotein responsible for platelet ag-
gregation and adhesion [3]. The three main types of VWD are type 1, a
partial quantitative deficiency of VWF, which is the most common type;
type 2, a qualitative VWF defect, which is less common and is divided
into 4 subtypes (2A, 2B, 2M, 2 N), depending on the specific functional
defect; and type 3, a virtually complete deficiency of VWF, which is the
least common type [4]. Assays of plasma VWF include measurements of
VWF functional activity (VWF:ristocetin cofactor [RCo]), VWF level
(VWF:antigen [Ag]), factor VIII coagulant activity (FVIII:C), collagen
binding (VWF:CB), and characterization of the VWF multimeric profile
(VWF multimers) [2,5]. Although all of these assays are used to es-
tablish a correct diagnosis of VWD, it is primarily the FVIII:C assay, and
sometimes the VWF:RCo assay, that is used to evaluate and monitor
replacement therapy.
The numerous VWF phenotypic presentations may require the use of
different treatments, depending on the particular clinical situation
[4,5]. Consequently, there is a need for optimal treatment based on
personalized, comprehensive, lifelong care [5].
1.1. Overview of the use of desmopressin in VWD
For many patients with VWD, endogenous recruitment of VWF and
factor VIII (FVIII) with desmopressin is a frequent treatment choice [6];
however, desmopressin is effective only if adequate and functionally
normal cellular VWF is present [5]. Thus, the overall clinical response
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to desmopressin is poor or absent in patients with type 3 VWD or
variants of type 2 VWD (e.g. patients with altered VWF-dependent
platelet adhesion [types 2B and 2M], high-molecular-weight VWF
multimer deficiencies or abnormalities [type 2A], or decreased binding
affinity for FVIII [type 2 N]) [5], and patients with more severe type
1 VWD (VWF:RCo activity< 10 IU/dL or FVIII activity< 20 IU/dL)
[7,8]. In addition, the treatment response to desmopressin in the subset
of patients with type 1 VWD with markedly decreased VWF survival in
plasma may be inadequate or transient [9], although desmopressin can
be recommended as first-line therapy for minor surgery and bleeding in
most patients with type 1 VWD [5]. However, desmopressin is limited
by tachyphylaxis [2], and prospective data correlating the biologic re-
sponse to desmopressin with efficacy are lacking. Concerns about
adverse events (e.g. hyponatremia) may also deter the use of
desmopressin [6]. Hematologists may prefer VWF replacement over
desmopressin in certain clinical situations (e.g. childbirth, major
surgery, children< 2 years of age, elderly patients with a history of
heart disease, and patients with extensive comorbidities) [4]. Most
plasma-derived concentrates for the treatment of VWD contain both
VWF and FVIII in varying proportions; this has implications for the
dosing of each product, which must consider both VWF:RCo units as
well as FVIII units [4,5]. Recombinant VWF (rVWF) does not contain
FVIII and it is only necessary to coadminister FVIII with the initial in-
fusion of rVWF in patients where the baseline plasma FVIII:C level
is< 40% (or unknown) or in situations where a rapid correction of
hemostasis is needed (such as acute hemorrhage, severe trauma, or
emergency surgery) [10].
1.2. Evolution of factor replacement therapies for VWD
Replacement therapies for VWD have evolved slowly over the past
several decades (Fig. 1 [1,11,12]) compared with those for less common
inherited bleeding disorders, such as hemophilia [1]. The earliest factor
replacement therapies for VWD were crude plasma protein prepara-
tions, such as plasma fraction I-O, developed in 1956, which restored
bleeding time and FVIII levels and was characterized by giving an early
rise in endogenous FVIII levels caused by the decreased FVIII clearance
associated with the infusion of VWF [1]. In 1964, it was found that
crude preparations derived from plasma cryoprecipitate were effective
and easy to produce, and plasma cryoprecipitate was widely used for
many years thereafter [1]. However, as with fraction I-O, its use carried
a risk of transmission of blood-borne infections owing to the fact that it
was not possible at that time to apply virucidal methods to cryopreci-
pitate production [1,13].
The need to circumvent this limitation led to the development of
more purified plasma-derived concentrates produced using various
methods of viral inactivation, starting with pasteurized FVIII/VWF
concentrate in 1981 [1]. These concentrates contain varying ratios of
VWF to FVIII, specific activities, and half-lives. They also contain
varying proportions of high-molecular-weight VWF multimers (but
none contain ultra-large multimers [ULMs]) because of differences in
purification and production methods. In vitro data suggest that higher-
molecular-weight multimers are physiologically more similar to en-
dothelial cell and platelet VWF [14], have a greater FVIII binding ca-
pacity, and are more effective in restoring hemostasis than smaller
multimers [15,16]. In addition, ULMs bind glycoprotein Ib (GpIb) of
platelets, an interaction that has an important role in hemostasis in the
gastrointestinal (GI) tract [17]. Variations in FVIII content and mul-
timer profiles among concentrates may translate to potential differences
in efficacy and/or risk of FVIII accumulation along with the potential
risk of thrombosis in certain situations [18]. Such differences among
concentrates contributed to the lack of a standardized approach to
factor replacement in patients with VWD.
More recently, a plasma-derived concentrate with a VWF:RCo/FVIII
ratio ≥10 (Wilfactin/Willfact) was approved in countries outside of the
United States, and a human recombinant form of VWF (rVWF) was
approved in the United States and Europe for the treatment of VWD.
Products that limit a patient's exposure to FVIII allow physicians to treat
the primary dysfunction of VWD and to individualize therapy based on
the bleed phenotype. This allows for more frequent dosing of VWF if
needed, without the risk of accumulation to supranormal levels of FVIII.
In this article, we discuss the evolution of these therapies with assay
evaluation, together with the clinical efficacy and safety of the cur-
rently available types of factor replacement therapies for VWD, to help
clinicians develop a more personalized approach to therapy for the
individual patient's needs.
2. Methods
2.1. Classification of therapies for VWD
For our discussion, we have categorized factor replacement thera-
pies for VWD into the following three groups: (1) cryoprecipitate, (2)
plasma-derived products with VWF:RCo/FVIII content ratios< 10 and
≥10, and (3) recombinant VWF. For groups 2 and 3, we carried out a
systematic literature search of clinical trials in patients with VWD, as
described below.
2.2. Search strategy
A PubMed database search (January 2000–March 2017) for clinical
trials of factor replacement therapies approved for VWD was per-
formed. Each of the search terms—“Alphanate,” “Fanhdi,” “Humate-P”
OR “Haemate-P,” “Voncento” OR “Biostate,” “Wilate,” “Wilfactin” OR
“Willfact,” and “rVWF” OR “Vonvendi”—was used in combination
(AND) with the term “von Willebrand Disease” OR “VWD.”
Retrospective/prospective studies evaluating hemostatic efficacy and
safety in diverse VWD patient types were included. Case reports and
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Fig. 1. Developmental progression of therapies
available for VWD. Thirty years after VWD was de-
scribed by Erik von Willebrand, the first plasma
fraction replacement therapy was introduced, fol-
lowed several years later by use of a plasma cryo-
precipitate. Subsequent efforts were directed at de-
veloping virus-inactivated preparations to deliver
VWF to decrease the risk of transmission of infec-
tion. The first pdVWF- and FVIII-containing con-
centrate, a pasteurized preparation, became avail-
able in the United States almost 20 years ago [1]. An
rVWF became available in late 2015 [11], following
completion of its phase 3 trial [12]. FDA, US Food
and Drug Administration; FVIII, factor VIII; pdVWF,
plasma-derived VWF; rVWF, recombinant VWF;
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studies with< 20 patients (Immunate, Dried Factor VIII Fraction Type
8Y) were excluded.
2.3. Literature search results
The available factor replacement therapies for patients with VWF
are outlined in Table 1 [5,11,18–28]. The literature search strategy
identified 274 studies (Wilate® [n=15], Alphanate® [n=36], Fanhdi®
[n=9], Voncento/Biostate® [n=9], Humate-P/Haemate-P®
[n=152], Wilfactin/Willfact® [n=2], rVWF or Vonvendi® [n=51]).
Of these, 21 publications met the inclusion criteria. Results are orga-
nized by class and summarized in Table 2 [11,12,19,24–26,29–50].
3. Results
3.1. Cryoprecipitate
Cryoprecipitate was the earliest (1964) commonly used form of
replacement therapy for VWD and was used to treat bleeding in patients
with VWD as late as 1995 [1]. Cryoprecipitate use is no longer re-
commended in Europe or the United States [51]; however, it remains in
use in countries where specific concentrates are not available [1]. Ad-
vantages were that it could be prepared rapidly from cold fractions of
fresh-frozen plasma and that it corrected hemostatic defects to restore
normal bleeding times [52]. However, a key disadvantage was that
virucidal methods were not available at that time to be applied in the
production of cryoprecipitate, which resulted in risk of transmission of
blood-borne infections [13]. Now, virus-inactivated cryoprecipitate is
also available in a limited number of countries.
3.2. Plasma-derived factor concentrates
Plasma-derived concentrates, the first of which became available in
Germany in 1981, were able to undergo viral inactivation, resulting in a
much lower risk of blood-borne infection compared with cryoprecipi-
tate. Initial FVIII concentrates prepared by chromatography and sub-
jected to virus-inactivation procedures were used for the treatment of
hemophilia; however, their low content of VWF rendered them in-
effective for the treatment of VWD [1]. Since 1981, several plasma-
derived VWF/FVIII concentrates have become available worldwide to
treat individuals with VWD (Table 1) [19–28]. They vary in method of
purification, method of viral inactivation, ratio of VWF to FVIII, and
VWF activity. Drawbacks to the use of these plasma-derived con-
centrates include a small risk of unknown pathogen transmission and
the inability to administer VWF separately from FVIII [5]. The summary
of product characteristics for one plasma-derived VWF/FVIII con-
centrate notes that, for products prepared from human blood, the
possibility of transmitting infective agents cannot be totally excluded
[25]. In a recent study investigating the US hemophilia treatment
centers, the US Centers for Disease Control and Prevention found that
all patients treated for VWD were using plasma-derived products owing
to the lack of a recombinant alternative [53]. The inability to com-
pletely remove parvovirus B19 by conventional virus inactivation and
reduction procedures is a limitation of these products. Good evidence
exists to suggest that the adhesive activity of VWF depends upon the
size of its multimers; those of high molecular weight (HMW) 5000 to
10,000 KDa and ULMs of> 10,000 KDa are the most hemostatically
active, being more effective at binding collagen and platelet receptors
to facilitate platelet aggregation and wound healing [54]. Plasma-de-
rived VWF concentrates do not have an intact multimeric structure,
being deficient in the larger, more hemostatically active multimers
because of their exposure to the VWF-cleaving protease ADAMTS13
during manufacture [5,14,55]. rVWF is not exposed to ADAMTS13 and,
therefore, contains a full multimeric profile [14], including the HMW
multimers and ULMs typically seen only in platelets and endothelial
cells [56].
3.2.1. Products with VWF:RCo/FVIII ratio ≤ 1
In patients requiring a greater increase in FVIII:C level, products with a
VWF:RCo/FVIII ratio≤1 could be beneficial in potentially enabling the
correction of both the primary VWF defect and, in some patients, a low
FVIII level. The von Willebrand factor/coagulation FVIII complex (Wilate),
a plasma-derived concentrate with a VWF:RCo/FVIII ratio of 0.8 to 1.0, was
approved for the treatment of VWF in 2009 [5,18]. In the production of this
concentrate, the mixture of VWF and FVIII is purified from plasma via ion
exchange and size-exclusion chromatography. Viral inactivation is achieved
by subjecting the sample to solvent/detergent plus dry heat [57]. As sum-
marized in Table 2, results of clinical trials in patients with all three types of
VWD showed excellent or good hemostatic efficacy in>95% of patients
treated for spontaneous or trauma-induced bleeds and patients undergoing
surgery [30,32,42,50,58]. The concentrate was also effective in patients
requiring prophylaxis [30,32,42]. In these trials, no marked FVIII accu-
mulation or thromboembolic events were observed [30,32,42,49,50] and
no patient developed alloantibodies [30,32,42,49,50] or transfusion-related
infections [30,32,49,50]. In a pooled analysis of four prospective clinical
trials in 44 patients with VWD of all types, efficacy was rated as excellent or
good in 96% of all treated bleeding episodes [32]. Bleeding was stopped in
a mean of 1.93 treatment days, with a mean dose per treatment day of
29 IU/kg. However, the number of infusions required to achieve hemostasis
and mean dose varied by bleed site (range 1.35 treatment days for me-
norrhagia to 4.23 treatment days for GI bleeds; 23 IU/kg/d for muscle/soft
tissue bleeds to 44 IU/kg/d for GI bleeds) and VWD type (range 1.24
treatment days for type 1 VWD to 3.97 treatment days for type 2 VWD;
28 IU/kg/d for type 1 VWD to 36 IU/kg/d for type 2 VWD).
3.2.2. Products with VWF:RCo/FVIII ratio> 1 to< 10
Four plasma-derived products with a VWF:RCo/FVIII ratio> 1
to< 10 are available for the treatment of VWD [5,18,59]. Two are
purified with heparin ligand chromatography (Alphanate and Fanhdi),
one with size-exclusion chromatography (Voncento/Biostate), and one
with multiple precipitation steps (Humate-P/Haemate-P) [21,57]. For
viral inactivation, three are treated with solvent/detergent plus dry
heat (Alphanate, Fanhdi, and Voncento/Biostate) and one is pasteur-
ized (Humate-P/Haemate-P) [21,57]. In patients with each of the three
types of VWD, all of these concentrates have achieved high rates of
excellent or good hemostatic efficacy as an on-demand treatment of
bleeding episodes (range 67–97%) as well as for patients undergoing
surgery (range 90–100% overall; Table 2). In addition, three con-
centrates (Alphanate, Voncento/Biostate, and Humate-P/Haemate-P)
have been investigated for their efficacy as prophylaxis and have de-
monstrated high rates of success (range 87–100%; Table 2). In a clinical
trial of antihemophilic factor/von Willebrand factor complex (human)
(Humate-P/Haemate-P) for the treatment of emergency bleeding epi-
sodes in patients with VWD (n=33), hemostatic efficacy was rated as
excellent/good for 52 of 53 events [60]. In total, 45 loading doses
(median [range] 67.0 [25.7–143.2] IU/kg) were administered, and 30
patients continued treatment for 1 to 3 days (mean 1.13 infusions/d),
22 patients for 4 to 7 days (mean 1.04 infusions/d), and 7 patients
for> 7 days (mean 0.78 infusions/d). The median number of infusions
per patient ranged from 1 in patients with type 3 VWD to 10 in patients
with type 1 VWD. Patients with orthopedic or neurologic events were
treated the longest (median 6 and 5 days, respectively). Overall, the
median (range) daily maintenance dose per infusion was 74.0
(16.4–182.9) IU/kg, with a median (range) of 2 (1–36) infusions per
event and a median (range) treatment duration of 3 (1–67) days. In the
clinical studies reviewed in Table 2, all four concentrates were well
tolerated. Thrombotic complications occurred in two patients treated
with Alphanate in one study and were managed medically, without
compromising treatment [46]; no other thrombotic complications were
reported in any of the other studies. One case of B19 parvovirus in-
fection occurred in a study of Alphanate [46]; no other treatment-re-
lated infections were reported in any of the other studies. Reported mild
adverse events possibly related to treatment were eye edema and
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infusion-site pruritus in a study of Voncento [45], and nausea in a study
of Biostate [41].
3.2.3. Products with VWF:RCo/FVIII ratio≥ 10
Currently, human von Willebrand factor (Wilfactin/Willfact) is the
only plasma-derived VWF concentrate that is almost devoid of FVIII
(VWF:RCo/FVIII ratio 10:≤ 1) and may be administered without ad-
ditional FVIII concentrate in the appropriate clinical setting [28,33,39].
It is purified by ion exchange and affinity chromatography, and viral
inactivation is accomplished using solvent/detergent treatment, 35-nm
filtration, and dry heating [57]. It has demonstrated high rates of he-
mostatic efficacy for on-demand treatment of bleeding in patients with
all types of VWD (89% rated excellent/good) [33,39], and for pro-
phylaxis of bleeding (100% success in preventing bleeds associated with
sporting activities or ovulation period) [33] and during surgical or in-
vasive procedures (100% rated excellent/good) in patients with type 3
VWD [33] (Table 2). For spontaneous bleeding, median infused dosage
was 41.8 IU/kg, with a median of 3 infusions per episode [33]. In most
cases (62%), treatment of spontaneous bleeding episodes did not re-
quire concomitant FVIII administration. For surgical prophylaxis,
median infused dosage was 45.5 IU/kg, with a median (range) of 3
(1–46) infusions across procedures and a median (range) exposure of 3
(1–37) days. No patient experienced clinically overt thrombosis, dis-
played evidence of FVIII accumulation, developed a transfusion-related
infection, or had detectable levels of anti-VWF:RCo antibodies [33].
3.3. Recombinant VWF
The first rVWF, vonicog alfa, is approved for on-demand treatment
and control of bleeding episodes and perioperative management of
bleeding in the United States [11], and for the treatment of hemorrhage
and surgical bleeding and prevention of surgical bleeding in Europe
[10] (Table 1). Unlike the plasma-derived products containing VWF and
FVIII at predefined ratios< 10:1, vonicog alfa, which has a VWF:RCo/
FVIII ratio of 100:≤ 1, may be administered independently if an im-
mediate rise in FVIII:C is not necessary or if baseline FVIII:C is sufficient
to ensure hemostasis (≥40%). In the elective surgical setting, rVWF can
be given alone to raise endogenous FVIII:C when baseline FVIII:C
is< 40% [10,11]. In contrast to the plasma-derived VWF replacement
therapies, which do not contain any ULMs, vonicog alfa is not exposed
to ADAMTS13 during manufacturing and thus contains hemostatically
effective ULMs during initial infusion. In vitro and clinical data indicate
that the ULMs in rVWF may help stabilize FVIII via platelet GpIb
binding [14,61,62], which could promote sustained VWF and FVIII
activity without the administration of additional FVIII. Following in-
fusion, the ULMs undergo rapid proteolysis, indicating the appropriate
susceptibility of vonicog alfa to physiologic regulation by ADAMTS13
[61] (Fig. 2). Given the rapid proteolysis, the risk for thrombosis seems
quite low, but does necessitate further study, particularly in high-risk
prothrombotic situations like pregnancy and orthopedic surgery.
Vonicog alfa has been evaluated in patients with severe VWD
[12,61,63]. In patients given a single dose of vonicog alfa + FVIII at a
fixed ratio of 1.3:1 or plasma-derived VWF/FVIII (Humate-P/Haemate-P),
outcomes indicated a higher specific activity (VWF:RCo/VWF:Ag) and
significantly enhanced FVIII stabilization for vonicog alfa + FVIII com-
pared with plasma-derived VWF/FVIII (P < 0.01). Improved stabiliza-
tion suggests the potential to achieve sustained FVIII activity, and in
comparing the two treatment groups, vonicog alfa + FVIII was associated
with a greater secondary rise in endogenous FVIII (Fig. 3), with FVIII:C
being significantly higher 72 h after administration (P < 0.01). Coad-
ministration of vonicog alfa and FVIII was not associated with the de-
velopment of clinically significant inhibitors or thrombosis [61]. The half-
life of VWF:RCo was 21.9 h with vonicog alfa alone and 19.6 h when
vonicog alfa was coadministered with FVIII (Fig. 4). A pharmacokinetic
assessment of VWF:RCo analyzed from data combined from the phase 1
and phase 3 on-demand studies, indicated a significantly longer terminal
half-life with vonicog alfa (50 IU/kg VWF:RCo) with or without FVIII
(38.5 IU/kg) (P < 0.05) than after administration of plasma-derived (pd)
pdVWF and pdFVIII (50 IU/kg pdVWF:RCo and 38.5 IU/kg pdFVIII) [10].
The hemostatic efficacy of on-demand treatment with vonicog alfa
(± FVIII) was rated as excellent (96.9%) or good (3.1%) for all
bleeding episodes in the phase 3 study [12]. In 81.8% of bleeds, a single
infusion was effective; the median number of infusions per bleed was 1
across all VWF types, bleed severities, bleed sites, and known bleed
causes, with the exception of major or severe bleeds (n=7 [3 joint, 3
GI, and 1 nasopharyngeal tract]; median 2 infusions/bleed) and 1 bleed
of unknown cause (3 infusions). The median dose administered per
bleed was 46.5 IU/kg. Treatment was not associated with the devel-
opment of neutralizing antibodies or thrombotic events, and there were
no serious infusion-related events [12].
The use of vonicog alfa in the surgical setting has also been eval-
uated in a phase 3 trial (Table 2) [63] and the safety profile was con-
sistent with that seen in the phase 3 on-demand study [12]. Ongoing
phase 3 clinical trials are studying the use of vonicog alfa as prophylaxis
(NCT02973087) and in pediatric patients (NCT02932618).
4. Discussion and conclusion
Factor replacement therapies for VWD are the mainstay of treatment
for patients who do not respond to or are intolerant of desmopressin or
other pharmacologic therapies [5,51]. Although the lack of prospective
head-to-head studies prohibits efficacy comparisons between agents,
we have described the beneficial effects of innovations in factor re-
placement therapy for VWF over the past several decades. Our analysis
shows that plasma-derived VWF/FVIII concentrates, which evolved
from cryoprecipitate to reduce the risk of transmission of infection,
have varying degrees of reported efficacy when used for on-demand
treatment, prophylaxis, and surgical hemostasis in patients with VWD.
In the studies reviewed here, investigators rated treatment efficacy as
excellent or good in most cases (67–100%), but comparative data are
lacking, and comparisons of additional endpoints, such as levels of
FVIII:C, VWF:RCo, high-molecular-weight multimers, and ULMs are of
interest. Plasma-derived products with high ratios of VWF:RCo to FVIII
provide good options for patients but also present challenges, owing to
the fact that they vary in VWF to FVIII ratios and activity, pharmaco-
kinetic profile, FVIII accumulation potential, and regional availability
[5]. Although thrombotic complications are rare with these agents, a
recent 33-year safety review of one such product indicated a potentially
higher risk in patients with VWD compared with patients with hemo-
philia A [64]. Overall, 33 thrombotic complications were identified
corresponding to one case per every 78,787 standard doses adminis-
tered. Twenty-four of the 33 cases were in patients with VWD. Hy-
persensitivity reactions (identified by the terms anaphylactic reaction,
anaphylactic shock, anaphylactoid reaction, hypersensitivity, angioe-
dema, and related terms) occurred in 110 cases overall, corresponding
to one case per every 23,636 standard doses administered, and 64%
occurred in patients with VWD [64]. These reactions may be related to
the plasma-derived nature of the product [64].
Furthermore, there is ongoing debate regarding which assay(s) (and
which biologic and pharmacologic functions of VWF) should be used to
monitor treatment of VWD [65]. Clarification of the appropriate assay
could help further individualize and advance lifelong VWF replacement
therapy via more informed treatment decisions. As new products
evolve, it will be important that corresponding progress is made with
laboratory measurements so that the most appropriate assay is used to
understand the beneficial effects of treatment, FVIII level, and VWF
activity. The traditional tests for monitoring VWD therapy are FVIII:C
and VWF:RCo [66]. These assays must be used in combination to de-
termine the VWD phenotype, but they are time consuming, difficult to
standardize, and limited to specialized laboratories [67]. These and
other limitations (e.g. high coefficient of variation and high limit of
detection with VWF:RCo assay) underscore the need to develop novel
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novel recombinant human von Willebrand factor manufactured
with a plasma-free method: a prospective clinical trial. Blood
122 (2013) 648–657 [61].)
F. Peyvandi, et al. Blood Reviews xxx (xxxx) xxx–xxx
8
assays that are simple and have greater accuracy, specificity, and sen-
sitivity [67–69]. Repeat assay testing is now necessary in the majority
of cases, which delays the diagnosis and treatment of patients with
VWD [67]. In vitro evidence suggests that the Platelet Function Ana-
lyzer-200, which is sensitive in detecting ULMs, could prove to be a step
forward in the monitoring of rVWF activity [70]. rVWF was shown to
normalize platelet function analyzer closure times in whole-blood
samples obtained from patients with VWD, whereas plasma-derived
VWF concentrates were not. Evidence-based treatment guidelines
should provide recommendations on the type of assays to be used with
the different VWF products available for the treatment of patients with
VWD [4,71]. The International Society on Thrombosis and Haemos-
tasis, American Society of Hematology, National Hemophilia Founda-
tion, and World Federation of Hemophilia are to develop clinical
practice guidelines on the diagnosis and management of VWD, due for
publication in 2020 [72].
Although the treatment of VWD has progressed, it remains a chal-
lenge, particularly with regard to accurately diagnosing and treating
major bleeds. There is also a need for treatment options that support an
effective, individualized approach in accordance with a patient's type
and clinical scenario. Replacement of deficient or dysfunctional VWF
and correction of reduced levels of FVIII are both important in restoring
hemostasis in patients with VWD [3]. Plasma-derived products with
VWF:RCo/FVIII ratios ≥10 (Wilfactin/Willfact) and rVWF products can
successfully treat bleeding episodes without concomitant FVIII admin-
istration in the majority of patients, particularly in situations not
needing an immediate attainment of hemostatic levels of FVIII. This
affords increased flexibility with regard to the amount of FVIII ad-
ministered, repeat dosing, and treatment individualization. FVIII ac-
cumulation is a concern, particularly when repeated dosing is necessary
(e.g. surgery, prophylaxis, postpartum, GI bleeding) and in the elderly,
and plasma-derived products with low or equal VWF content relative to
FVIII may increase the potential risk for thrombotic events in these
patients [73]. Independent administration of rVWF or purified pdVWF
and FVIII enables independent optimization of plasma FVIII and VWF.
This could improve efficacy and safety by allowing clinicians to address
and optimize the primary deficiency in VWF without the concern of
FVIII overaccumulation. Many patients with VWD have specific needs
and would benefit from a more personalized treatment approach and
advanced replacement therapy, particularly tailoring coadministration
of FVIII. Examples include surgical (specifically major surgeries that
may require frequent postoperative doses), obstetrical, gynecological
(heavy menstrual bleeding), and elderly patients, populations at risk for
thrombosis and for whom clinicians must balance the desire for optimal
efficacy with the concern for FVIII overaccumulation; patients with
bleeding associated with loss of ULMs (e.g. GI bleeding) for whom re-
storation theoretically could enhance bleed resolution; and patients
receiving prophylaxis and desiring a longer VWF half-life in hopes of
reducing the frequency of infusions. Patients who experience anaphy-
lactic or allergic reactions to plasma-derived products, patients not
responding to plasma-derived high-VWF-content products, patients
with relatively high levels of FVIII who do not require any additional
FVIII (e.g. patients with type 1, 2A, or 2B VWD), and patients living in
remote locations where storage and reconstitution of plasma-derived
products are either cumbersome or not possible might also benefit from
such an approach. Additional data regarding vonicog alfa are needed.
In particular, there is a need to investigate the mechanisms underlying
the extended half-life and FVIII stabilizing properties of vonicog alfa
[10] and the role of ULMs. Whether these properties will translate to
benefits for particular patient populations and improved hemostatic
efficacy for specific types of bleeds is an important area of ongoing
clinical research (Table 3). Although some evidence on the use of vo-
nicog alfa for menorrhagia and epistaxis is documented in the phase 3
on-demand study [12], as well as a subanalysis on the treatment of GI
bleeding [74], the hemostatic efficacy of vonicog alfa in challenging
clinical scenarios is an important area for future clinical research. Extra-
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Table 3
Potential areas for future clinical study of rVWF in patients with VWD.
Clinical setting Rationale for rVWF
AVM-related GI bleeding ULMs may inhibit angiogenesis
Pediatrics Multicenter, phase 3 study in patients < 18 years of age is ongoing (NCT02932618)
Prophylaxis Multicenter, phase 3 study is ongoing (NCT02973087)
AVM, arteriovenous malformation; GI, gastrointestinal; rVWF, recombinant VWF; ULM, ultra-large multimer; VWD, von
Willebrand disease; VWF, von Willebrand factor.
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intestinal angiodysplasia is a big challenge in the treatment of patients
with VWD, particularly in the elderly, as well as in those with refractory
epistaxis [75]. Real-world data, especially in the pediatric population
and the prophylaxis setting, would help to further inform the clinical
use of rVWF.
The management of VWD is complex, and global standardization for
biologic therapies and clear guidance for treatment are currently
lacking. Although clarification is needed regarding the optimal order of
factor replacement therapies in a treatment algorithm, marked tech-
nological achievements—from the development of the first plasma-
derived VWF concentrates to the recent rVWF product—should allow
clinicians to further individualize and control VWF replacement
therapy for patients with VWD.
Practice Points
• There is currently no standardized approach to factor replacement
therapy in VWD.• The more recently available factor replacement therapies may pro-
vide flexibility to control the amount of FVIII administered along
with VWF, allowing for individualization of therapy.• It is important to understand which assays will be most appropriate
for use with the new VWF replacement therapies that have become
available.
Research Agenda
• Determination of the role of rVWF in prophylaxis against sponta-
neous bleeding episodes.• Determination of the effects of new products on mucosal and GI
bleeds.• Development of assays to evaluate the treatment efficacy of new
products.• Development of assays to evaluate the role of ULMs in hemostasis in
clinical situations.
Funding
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
Initial medical writing support for this manuscript was provided by
Meg Shurak, MS, and Stephanie Leinbach, PhD, employees of C4
MedSolutions, LLC, a CHC Group company (Yardley, PA, USA), and was
funded by Baxalta US Inc., a member of the Takeda group of companies.
Editorial support for this manuscript was provided by Isobel Lever,
PhD, employee of Excel Medical Affairs (Southport, CT, USA) and
funded by Baxalta US Inc., a member of the Takeda group of companies.
Disclosures
F. Peyvandi has received honoraria for participating as a speaker at
educational meetings by Ablynx, Alnylam, F. Hoffmann-La Roche,
Grifols, Shire*, and Sobi. She is a member of the Ablynx, F. Hoffmann-
La Roche, and Shire* advisory boards. She did not receive honoraria
from Shire* for this work.
P. Kouides has received honoraria consulting with CSL Behring,
Octapharma, and Shire*.
P. L. Turecek is an employee of Baxalta Innovations GmbH, a
member of the Takeda group of companies, and stock owner of Takeda
Pharmaceutical Company Limited.
E. Dow was an employee of Baxalta US Inc., a member of the Takeda
group of companies, Cambridge, MA, USA, at the start of development
of this review and is now an employee of the Norfolk Center for Cancer
Care & Hematology, Brockton, MA, USA and Consulting Medical
Director of Epizyme Inc., Cambridge, MA, USA.
E. Berntorp has received speaker honoraria and/or research support
from CSL Behring, Grifols, LFB, Octapharma, and Shire*.
*Shire is now a member of the Takeda group of companies.
Acknowledgments
F. Peyvandi, P. Kouides, P. L. Turecek, E. Dow, and E. Berntorp
developed the concept of the manuscript, provided substantial input
and direction on the intellectual content, including resources, and cri-
tically revised the manuscript and approved the final version for pub-
lication. Although employees of Baxalta Innovations GmbH, a member
of a the Takeda group of companies, were involved in the design, col-
lection, analysis, interpretation, fact checking of information, and co-
ordination and collation of comments, the content of this manuscript,
the interpretation of the content, and the decision to submit the
manuscript for publication in Blood Reviews was made by the authors.
References
[1] Federici AB, Berntorp E, Lee CA. The 80th anniversary of von Willebrand's disease:
history, management and research. Haemophilia 2006;12:563–72.
[2] Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of
symptomatic von Willebrand disease in primary care practice. J Thromb Haemost
2010;8:213–6.
[3] Leebeek F, Eikenboom J. Von Willebrand's disease. New Engl J Med
2016;375:2067–80.
[4] Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL,
et al. von Willebrand disease (VWD): evidence-based diagnosis and management
guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel
report (USA). Haemophilia 2008;14:171–232.
[5] Favaloro EJ. Towards personalised therapy for von Willebrand disease: a future role
for recombinant products. Blood Transfus 2016;14:262–76.
[6] Neff AT. Current controversies in the diagnosis and management of von Willebrand
disease. Ther Adv Hematol 2015;6:209–16.
[7] Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al.
Biologic response to desmopressin in patients with severe type 1 and type 2 von
Willebrand disease: results of a multicenter European study. Blood
2004;103:2032–8.
[8] American Society of Hematology Working Group. Clinical Practice Guideline on the
Evaluation and Management of von Willebrand Disease (VWD). www.hematology.
org/Clinicians/Guidelines-Quality/Quick-Ref/528.aspx; 2012, Accessed date: 18
November 2016.
[9] Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al.
Response to desmopressin is influenced by the genotype and phenotype in type 1
von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.
Blood 2008;111:3531–9.
[10] European Medicines Agency. Veyvondi. 650 IU, 1300 IU (powder and solvent for
solution for injection). Summary of Product Characteristics. Vienna, Austria:
Baxalta Innovations GmbH; 2018.
[11] US Food and Drug Administration. Vonvendi® [von Willebrand factor (re-
combinant)]. Lyophilized powder for solution for intravenous injection. Full pre-
scribing information. Lexington, MA: Baxalta US Inc.; 2018.
[12] Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, et al. Hemostatic
efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in
severe von Willebrand disease. Blood 2015;126:2038–46.
[13] Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in
the year 2003: towards the complete identification of gene defects for correct di-
agnosis and treatment. Haematologica 2003;88:94–108.
[14] Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, et al.
Development of a plasma- and albumin-free recombinant von Willebrand factor.
Hamostaseologie 2009;29(Suppl. 1):S32–8.
[15] Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von
Willebrand factor/factor VIII concentrates: impact on treatment of patients with
von Willebrand disease. Semin Thromb Hemost 2006;32:626–35.
[16] Batlle J, Lopez-Fernandez MF, Fraga EL, Trillo AR, Perez-Rodriguez MA. Von
Willebrand factor/factor VIII concentrates in the treatment of von Willebrand dis-
ease. Blood Coagul Fibrinolysis 2009;20:89–100.
[17] Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied
issues. J Thromb Haemost 2017;15:13–20.
[18] Miesbach W, Berntorp E. Interaction between VWF and FVIII in treating VWD. Eur J
Haematol 2015;95:449–54.
[19] US Food and Drug Administration. Alphanate® (antihemophilic factor/von
Willebrand factor complex [human]). Sterile, lyophilized powder for injection. Full
prescribing information. Los Angeles, CA: Grifols Biologicals Inc.; 2015.
[20] Electronic Medicines Compendium. Alphanate® (powder for injection). Summary of
product characteristics. Barcelona, Spain: Instituto Grifols; 2016.
[21] Biostate®. Human coagulation factor VIII (FVIII) and human von Willebrand factor
(VWF) complex, powder for injection. Consumer Medicine Information.
Broadmeadows VIC, Australia: CSL Behring (Australia) Pty Ltd; 2017.
[22] Electronic Medicines Compendium. Fanhdi®. Human coagulation factor VIII, Ph.
Eur. (25, 50, 100 IU/ml powder and solvent for solution for injection). Summary of
F. Peyvandi, et al. Blood Reviews xxx (xxxx) xxx–xxx
10
product characteristics. Barcelona, Spain: Instituto Grifols, S.A; 2018.
[23] Electronic Medicines Compendium. Haemate-P® (1000 IU powder and solvent for
solution for injection or infusion). Summary of product characteristics. Marburg,
Germany: CSL Behring GmbH; 2018.
[24] Humate-P®. (antihemophilic factor/von Willebrand factor complex [human]) lyo-
philized powder for reconstitution for intravenous use only. Full prescribing in-
formation. Kankakee, IL: CSL Behring LLC; 2014.
[25] Electronic Medicines Compendium. Voncento® (1000 IU FVIII / 2400 IU VWF [10
ml solvent] powder and solvent for solution for injection/infusion). Summary of
product characteristics. Marburg, Germany: CSL Behring GmbH; 2018.
[26] US Food and Drug Administration. Wilate®, von Willebrand factor/coagulation
factor VIII complex (human). Lyophilized powder for solution for intravenous in-
jection. Full prescribing information. Hoboken, NJ, USA: Octapharma USA Inc.;
2015.
[27] Electronic Medicines Compendium. Wilate® (powder and solvent for solution for
injection). Summary of product characteristics. Manchester, UK: Octapharma
Limited; 2014.
[28] Electronic Medicines Compendium. Willfact/Willfactin® (1000 IU powder and sol-
vent for solution for injection). Summary of product characteristics. London, UK:
LFB Biopharmaceuticals Limited; 2016.
[29] Abshire TC, Federici AB, Alvarez MT, Bowen J, Carcao MD, Cox Gill J, et al.
Prophylaxis in severe forms of von Willebrand's disease: results from the von
Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013;19:76–81.
[30] Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ. Safety and efficacy of a von
Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Haemophilia 2014;20:846–53.
[31] Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von
Willebrand's disease: prospective international study results. Haemophilia
2007;13(Suppl. 5):25–32.
[32] Berntorp E, Windyga J, European Wilate Study Group. Treatment and prevention of
acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new
generation von Willebrand factor/factor VIII concentrate. Haemophilia
2009;15:122–30.
[33] Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I,
et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand
factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb
Haemost 2007;5:1115–24.
[34] Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, et al. Clinical efficacy
and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in pa-
tients with von Willebrand's disease: a prospective multi-centre study. Haemophilia
2010;16:615–24.
[35] Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, et al.
Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII con-
centrates in inherited von Willebrand's disease: results of an Italian cohort study on
120 patients characterized by bleeding severity score. Haemophilia
2010;16:101–10.
[36] Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, et al.
Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von
Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease:
a retrospective clinical study. Haemophilia 2002;8:761–7.
[37] Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, et al.
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on
100 Italian patients. Haematologica 2007;92:944–51.
[38] Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, et al. von
Willebrand factor/factor VIII concentrate (Humate-P) for management of elective
surgery in adults and children with von Willebrand disease. Haemophilia
2011;17:895–905.
[39] Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, et al.
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a
low factor VIII content treated with three virus-inactivation/removal methods. J
Thromb Haemost 2005;3:2219–27.
[40] Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-
Morata R. Clinical efficacy in bleeding and surgery in von Willebrand patients
treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Haemophilia 2008;14:963–7.
[41] Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, et al. The clinical
efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von
Willebrand disorder: a multi-centre retrospective review. Haemophilia
2011;17:463–9.
[42] Khair K, Batty P, Riat R, Bowles L, Burgess C, Chen YH, et al. Wilate use in 47
children with von Willebrand disease: the North London paediatric haemophilia
network experience. Haemophilia 2015;21:e44–50.
[43] Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, Haemate P Surgical
Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing
based on pharmacokinetics: a prospective multicenter trial in elective surgery. J
Thromb Haemost 2007;5:1420–30.
[44] Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia
Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand
factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients
with von Willebrand disease. Thromb Haemost 2002;87:224–30.
[45] Lissitchkov TJ, Buevich E, Kuliczkowski K, Stasyshyn O, Cerqueira MH, Klukowska
A, et al. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII
concentrate (VONCENTO) for on-demand and prophylactic treatment in patients
with von Willebrand disease (SWIFT-VWD study). Blood Coagul Fibrinolysis
2017;28:152–62.
[46] Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al.
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand
factor concentrate: a prospective, multicenter study. Blood 2002;99:450–6.
[47] Rivard GE, Aledort L, Alphanate Surgical Investigators. Efficacy of factor VIII/von
Willebrand factor concentrate Alphanate in preventing excessive bleeding during
surgery in subjects with von Willebrand disease. Haemophilia 2008;14:271–5.
[48] Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high
purity, double virus inactivated factor VIII/von Willebrand factor concentrate
(Biostate) in patients with von Willebrand disorder requiring invasive or surgical
procedures. Haemophilia 2007;13:144–8.
[49] Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM, Wonders Study
Investigators. Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited
von Willebrand disease patients undergoing surgical procedures. Haemophilia
2017;23:264–72.
[50] Windyga J, von Depka-Prondzinski M, European Wilate® Study Group. Efficacy and
safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®)
in the management of perioperative haemostasis in von Willebrand disease patients
undergoing surgery. Thromb Haemost 2011;105:1072–9.
[51] National Hemophilia Foundation. Medical and Scientific Advisory Council
(MASAC) recommendations concerning products licensed for the treatment of he-
mophilia and other bleeding disorders. Document #237. https://www.hemophilia.
org/sites/default/files/document/files/237Text.pdf, Accessed date: 18 November
2016.
[52] Perkins HA. Correction of the hemostatic defects in Von Willebrand's disease. Blood
1967;30:375–80.
[53] Soucie JM, De Staercke C, Monahan PE, Recht M, Chitlur MB, Gruppo R, et al.
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders
treated with plasma-derived factor concentrates in the era of nucleic acid test
screening. Transfusion 2013;53:1217–25.
[54] Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor
multimers: focus on high-molecular-weight multimers and their role in hemostasis.
Blood Coagul Fibrinolysis 2014;25:206–16.
[55] Mannuccio PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in
therapeutic plasma concentrates. Blood 1994;83:3018–27.
[56] Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first re-
combinant product licensed for the treatment of von Willebrand disease. Expert Rev
Hematol 2016;9:825–30.
[57] Castaman G, Goodeve A, Eikenboom J, European Group on von Willebrand Disease.
Principles of care for the diagnosis and treatment of von Willebrand disease.
Haematologica 2013;98:667–74.
[58] Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical out-
comes of omalizumab therapy in severe allergic asthma: study of efficacy and
safety. Respir Med 2017;124:36–43.
[59] Federici AB. Management of von Willebrand disease with factor VIII/von
Willebrand factor concentrates: results from current studies and surveys. Blood
Coagul Fibrinolysis 2005;16(Suppl. 1):S17–21.
[60] Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, Humate-P
Study Group. Successful treatment of urgent bleeding in von Willebrand disease
with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay
(VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003;9:688–95.
[61] Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, et al.
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor
manufactured with a plasma-free method: a prospective clinical trial. Blood
2013;122:648–57.
[62] Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto
fibrinogen or translocation on von Willebrand factor. Cell 1996;84:289–97.
[63] Peyvandi F, Mamaev A, Wang J-D, Stasyshyn O, Timofeeva M, Curry N, et al. Phase
3 study of recombinant von Willebrand factor in patients with severe von
Willebrand disease who are undergoing elective surgery. J Thromb Haemost
2019;17:52–62.
[64] Kouides P, Wawra-Hehenberger K, Sajan A, Mead H, Simon T. Safety of a pas-
teurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis
of 33 years of pharmacovigilance data. Transfusion 2017;57:2390–403.
[65] Mannucci PM, Franchini M. Laboratory monitoring of replacement therapy for
major surgery in von Willebrand disease. Haemophilia 2017;23:182–7.
[66] Favaloro EJ. A better approach to monitoring of therapy in von Willebrand disease?
Thromb Haemost 2008;100:371–3.
[67] James PD. VWD diagnosis: improved. Blood 2016;127:2372–3.
[68] Roberts JC, Morateck PA, Christopherson PA, Yan K, Hoffmann RG, Gill JC, et al.
Rapid discrimination of the phenotypic variants of von Willebrand disease. Blood
2016;127:2472–80.
[69] Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, et al. A highly-
sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay
by flow cytometry. J Thromb Haemost 2008;6:323–30.
[70] Pekrul I, Kragh T, Turecek PL, Novack A, Ott H, Spannagl M. Sensitive and specific
assessment of recombinant von Willebrand factor in platelet function analyzer.
Platelets 2019;30:264–70.
[71] Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis
and management of von Willebrand disease: a United Kingdom Haemophilia Centre
F. Peyvandi, et al. Blood Reviews xxx (xxxx) xxx–xxx
11
Doctors Organization guideline approved by the British Committee for Standards in
Haematology. Br J Haematol 2014;167:453–65.
[72] The International Society on Thrombosis and Haemostasis Press Release. ISTH to
collaborate on clinical practice guidelines on diagnosis, management of VWD.
https://www.isth.org/news/406042/ISTH-to-Collaborate-on-Clinical-Practice-
Guidelines-on-Diagnosis-Management-of-VWD.htm, Accessed date: November
2018.
[73] Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med
2004;351:683–94.
[74] Leebeek F, Chapman M, Ploder B, Sytkowski A, Novack A, Ewenstein B. Treatment
of gastrointestinal bleeding episodes with recombinant von Willebrand factor
(rVWF) in patients with severe von Willebrand disease (VWD): sub-analysis from
pivotal phase III on-demand study. Res Pract Thromb Haemost 2017;1:880.
[75] Quick AJ. Telangiectasia: its relationship to the Minot-von Willebrand syndrome.
Am J Med Sci 1967;254:585–601.
F. Peyvandi, et al. Blood Reviews xxx (xxxx) xxx–xxx
12
